Do BioCryst Pharmaceuticals Inc. (BCRX) beta value of 2.56 signposts another twist? – Invest Chronicle

Do BioCryst Pharmaceuticals Inc. (BCRX) beta value of 2.56 signposts another twist?

BioCryst Pharmaceuticals Inc. (BCRX) is priced at $14.99 after the most recent trading session. At the very opening of the session, the stock price was $14.82 and reached a high price of $15.01, prior to closing the session it reached the value of $14.71. The stock touched a low price of $14.59.Recently in News on October 4, 2021, BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 178,500 shares of BioCryst common stock on September 30, 2021 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). You can read further details here

BioCryst Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $18.48 on 08/06/21, with the lowest value was $7.27 for the same time period, recorded on 01/05/21.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


BioCryst Pharmaceuticals Inc. (BCRX) full year performance was 283.38%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, BioCryst Pharmaceuticals Inc. shares are logging -18.89% during the 52-week period from high price, and 333.24% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $3.46 and $18.48.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2508772 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the BioCryst Pharmaceuticals Inc. (BCRX) recorded performance in the market was 101.21%, having the revenues showcasing -5.13% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.59B, as it employees total of 246 workers.

Specialists analysis on BioCryst Pharmaceuticals Inc. (BCRX)

During the last month, 0 analysts gave the BioCryst Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 15.69, with a change in the price was noted +1.13. In a similar fashion, BioCryst Pharmaceuticals Inc. posted a movement of +8.15% for the period of last 100 days, recording 2,915,130 in trading volumes.

>> 7 Top Picks for the Post-Pandemic Economy << 

Trends and Technical analysis: BioCryst Pharmaceuticals Inc. (BCRX)

Raw Stochastic average of BioCryst Pharmaceuticals Inc. in the period of last 50 days is set at 35.13%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 71.48%. In the last 20 days, the company’s Stochastic %K was 58.69% and its Stochastic %D was recorded 49.21%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 101.21%. Additionally, trading for the stock in the period of the last six months notably improved by 32.19%, alongside a boost of 283.38% for the period of the last 12 months. The shares increased approximately by 10.79% in the 7-day charts and went up by -3.17% in the period of the last 30 days. Common stock shares were lifted by -5.13% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

More Posts

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam